NXC-201
Undisclosed Other Serious Diseases (Autoimmune/Immune-mediated)
Phase 1 / Phase 2IND-Enabled
Key Facts
Indication
Undisclosed Other Serious Diseases (Autoimmune/Immune-mediated)
Phase
Phase 1 / Phase 2
Status
IND-Enabled
Company
About Immix Biopharma
Immix Biopharma is a public company (NASDAQ: IMMX) focused on developing transformative cell therapies for serious diseases, starting with AL Amyloidosis. Its core innovation is the N-GENIUS platform, which produces sterically-optimized CAR-Ts designed to overcome neurotoxicity—the major barrier to CAR-T adoption. The company has achieved key milestones including FDA Breakthrough Therapy Designation for NXC-201, strong Phase 1b/2a clinical results (92% ORR), and recently closed a $100 million underwritten offering to advance its pipeline.
View full company profile